miGut-Health Project Begins Third Year: Reflecting on Progress and Setting Plans for 2025
As the miGut-Health project enters year three, partners have made crucial strides in advancing the understanding of gut health and inflammatory bowel disease (IBD). Over the past two years, the research teams have validated and identified biomarkers in relation to IBD and gut health, created personalised prevention measures, and developed digital tools further. For 2025, ambitious plans have been kickstarted to advance these milestones to improve patient outcomes.
As a partner in miGut-Health, Eurice plays a pivotal role in helping to advance this groundbreaking research initiative. "Our involvement builds on a strong track record of similar projects that span diverse aspects of chronic inflammatory diseases," says Verena Gluschak, Research & Innovation Manager at Eurice. "By collaborating with outstanding partners across Europe, we are proud to contribute to innovative solutions that make a tangible difference in people’s lives. We are excited to continue our commitment to this important field through miGut-Health, advancing knowledge in dietary interventions, biomarker discovery, and digital tools."
miGut-Health has made significant strides in identifying molecular markers of gut health and analysing genetic contributors to IBD. Novel findings include changes in microbiome profiles and antibody repertoires before diagnosis, alongside protein signatures that could aid in identifying Crohn's disease earlier. Cutting-edge tools are also being developed to integrate genetic and clinical data, enabling a more comprehensive approach to biomarker research.
Personalised prevention measures remain a key focus. Studies, such as those investigating the effects of long-term gluten-free diets and dietary compounds like tryptophan (an amino acid) and polyphenols (plant-based antioxidants), are yielding promising results. These efforts aim to improve inflammation management and quality of life for IBD patients.
Digital tools like MyIBDcoach, MyFoodRepo, and wearable devices are central to empowering patients. With these tools, patients can collect data that miGut-Health researchers use to develop machine learning models for more personalised IBD care. Patient engagement activities, including international surveys and workshops, are also helping to encourage proactive gut health management.
This year, Eurice will continue highlighting miGut-Health’s research efforts, such as the first-of-its-kind symposium "Science talks to the IBD community" in Torshavn, Faroe Islands, on 16 June, which will address the region's high incidence of IBD. In addition, the ongoing campaign "Voices from the IBD Community" continues to amplify the experiences of people living with IBD.
Stay updated on miGut-Health activities by following the project on LinkedIn, X, or visiting the website.
